Phase 1 clinical trial of ADI-001 in autoimmune diseases actively enrolling patients with lupus nephritis (LN), systemic lupus erythematosus (SLE) and SSc Preliminary clinical data from Phase 1 trial ...
Please provide your email address to receive an email when new articles are posted on . “ILD is detectable in up to 80% of patients with systemic sclerosis (SSc), and a leading cause of morbidity and ...
Phase 1 trial achieved primary objective of safety and tolerability and demonstrated favorable outcomes on other key endpoints, including target engagement and immunogenicity Discussion of Phase 1 ...
Age, specific disease-related elements, and treatment with glucocorticoids independently affect the risk for osteoporosis among patients with systemic sclerosis. Age, specific disease-related elements ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results